tbuckley/cabot-search huggingface dataset:
Loss of Endothelial Endoglin Promotes High-Output Heart Failure Through Peripheral Arteriovenous Shunting Driven by VEGF Signaling
Authors: Simon Tual-Chalot, Maria Garcia-Collado, Rachael E. Redgrave, Esha Singh, Benjamin Davison, Catherine Park, Hua Lin, Saimir Luli, Yi Jin, Yixin Wang, Allan Lawrie, Lars Jakobsson, Helen M. Arthur
Journal: Circulation Research (2019)

ENG (endoglin) is a coreceptor for BMP (bone morphogenetic protein) 9/10 and is strongly expressed in endothelial cells. Mutations in ENG lead to the inherited vascular disorder hereditary hemorrhagic telangiectasia characterized by local telangiectases and larger arteriovenous malformations (AVMs); but how ENG functions to regulate the adult vasculature is not understood.The goal of the work was to determine how ENG maintains vessel caliber in adult life to prevent AVM formation and thereby protect heart function.Genetic depletion of endothelial Eng in adult mice led to a significant reduction in mean aortic blood pressure. There was no evidence of hemorrhage, anemia, or AVMs in major organs to explain the reduced aortic pressure. However, large AVMs developed in the peripheral vasculature intimately associated with the pelvic cartilaginous symphysis-a noncapsulated cartilage with a naturally high endogenous expression of VEGF (vascular endothelial growth factor). The increased blood flow through these peripheral AVMs explained the drop in aortic blood pressure and led to increased cardiac preload, and high stroke volumes, ultimately resulting in high-output heart failure. Development of pelvic AVMs in this region of high VEGF expression occurred because loss of ENG in endothelial cells leads to increased sensitivity to VEGF and a hyperproliferative response. Development of AVMs and associated progression to high-output heart failure in the absence of endothelial ENG was attenuated by targeting VEGF signaling with an anti-VEGFR2 (VEGF receptor 2) antibody.ENG promotes the normal balance of VEGF signaling in quiescent endothelial cells to maintain vessel caliber-an essential function in conditions of increased VEGF expression such as local hypoxia or inflammation. In the absence of endothelial ENG, increased sensitivity to VEGF drives abnormal endothelial proliferation in local regions of high VEGF expression, leading to AVM formation and a rapid injurious impact on heart function.
The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt
Authors: Laurence Legros, Franck E Nicolini, Gabriel Etienne, Philippe Rousselot, Delphine Rea, Stephane Giraudier, Agnès Guerci, Francoise Huguet, Martine Gardembas, Jean-Christophe Ianotto, Martine Escoffre-Barbe, Valerie Coiteux, Bruno Varet, Stephane Morisset, Francois-Xavier Mahon
Journal: Blood (2019)
Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Authors: Hannah C. Beird, Maliha Khan, Feng Wang, Mansour Alfayez, Tianyu Cai, Li Zhao, Joseph Khoury, P. Andrew Futreal, Marina Konopleva, Naveen Pemmaraju
Journal: Blood Cancer Journal (2019)

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, male-predominant hematologic malignancy with poor outcomes and with just one recently approved agent (tagraxofusp). It is characterized by the abnormal proliferation of precursor plasmacytoid dendritic cells (pDCs) with morphologic and molecular similarities to acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) in its presentation within the bone marrow and peripheral blood. To identify disease-specific molecular features of BPDCN, we profiled the bone marrow, peripheral blood, and serum samples from primary patient samples using an in-house hematologic malignancy panel (“T300” panel), transcriptome microarray, and serum multiplex immunoassays. TET2 mutations (5/8, 63%) were the most prevalent in our cohort. Using the transcriptome microarray, genes specific to pDCs ( LAMP5, CCDC50 ) were more highly expressed in BPDCN than in AML specimens. Finally, the serum cytokine profile analysis showed significantly elevated levels of eosinophil chemoattractants eotaxin and RANTES in BPDCN as compared with AML. Along with the high levels of PTPRS and dendritic nature of the tumor cells, these findings suggest a possible pre-inflammatory context of this disease, in which BPDCN features nonactivated pDCs.
Serum Free-Lite Chain (sFLC) Assay in Multiple Myeloma (MM): Clinical Correlates and Prognostic Implications in Newly Diagnosed MM Patients Treated with Total Therapy 2 or 3 (TT2/3).
Authors: Federica Cavallo, Erik Rasmussen, Maurizio Zangari, Guido Tricot, Belinda Fender, Michelle Fox, Michael Burns, Bart Barlogie
Journal: Blood (2005)
PP-14, a Novel Structurally-Enhanced Antisickling Allosteric Hemoglobin Effector, Increases Oxygen Affinity and Disrupts Hemoglobin S Polymer Formation
Authors: Martin K. Safo, Piyusha P Pagare, Mohini Ghatge, Carla Casu, Valentina Ghiaccio, Nancy Anabaraonye, Xiaomeng Xu, Stefano Rivella, Patrick C. Hines, Ke Liu, Yan Zhang, Jürgen Venitz, Osheiza Abdulmalik
Journal: Blood (2019)
Agonist Anti-TRAILR1 Human Mab, Hgs-ETR1, Induces Myeloma Cell Death Mainly through the Intrinsic Pathway of Apoptosis.
Authors: Emmanuelle Ménoret, Sylvanie Surget, Patricia Gomez-Bougie, Régis Bataille, Martine Amiot, Catherine Pellat-Deceunynck
Journal: Blood (2008)
CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies
Authors: Alba Rodriguez-Garcia, Prannda Sharma, Mathilde Poussin, Alina C. Boesteanu, Nicholas G. Minutolo, Sarah B. Gitto, Dalia K. Omran, Matthew K. Robinson, Gregory P. Adams, Fiona Simpkins, Daniel J. Powell
Journal: Molecular Therapy (2019)

The prognosis of patients diagnosed with advanced ovarian or endometrial cancer remains poor, and effective therapeutic strategies are limited. The Müllerian inhibiting substance type 2 receptor (MISIIR) is a transforming growth factor β (TGF-β) receptor family member, overexpressed by most ovarian and endometrial cancers while absent in most normal tissues. Restricted tissue expression, coupled with an understanding that MISIIR ligation transmits apoptotic signals to cancer cells, makes MISIIR an attractive target for tumor-directed therapeutics. However, the development of clinical MISIIR-targeted agents has been challenging. Prompted by the responses achieved in patients with blood malignancies using chimeric antigen receptor (CAR) T cell therapy, we hypothesized that MISIIR targeting may be achieved using a CAR T cell approach. Herein, we describe the development and evaluation of a CAR that targets MISIIR. T cells expressing the MISIIR-specific CAR demonstrated antigen-specific reactivity in vitro and eliminated MISIIR-overexpressing tumors in vivo. MISIIR CAR T cells also recognized a panel of human ovarian and endometrial cancer cell lines, and they lysed a battery of patient-derived tumor specimens in vitro, without mediating cytotoxicity of a panel of normal primary human cells. In conclusion, these results indicate that MISIIR targeting for the treatment of ovarian cancer and other gynecologic malignancies is achievable using CAR technology.
Classification of Familial Hemophagocytic Lymphohistiocytosis Based on Genetic and Immunologic Analyses.
Authors: Eiichi Ishii, Ikuyo Ueda, Ken Yamamoto, Shouichi Ohga, Kenji Furuno, Akira Morimoto, Miyoko Imayoshi, Masahiro Sako, Hidetoshi Takada, Toshiro Hara, Shinsaku Imashuku, Takehiko Sasazuki, Masaki Yasukawa
Journal: Blood (2004)
A phase II study of patupilone in patients (pts) with metastatic castration- resistant prostate cancer (CRPC) who have progressed after docetaxel
Authors: E. K. Beardsley, F. Saad, B. Eigl, P. Venner, S. Hotte, E. Winquist, Y. J. Ko, S. S. Sridhar, K. N. Chi
Journal: Journal of Clinical Oncology (2009)

5139 Background: Chemotherapy for pts with CRPC who have progressed after docetaxel remains to be defined. Patupilone is an epothilone with broad spectrum pre-clinical activity including in taxane resistant models. Methods: Multicenter, 2-stage design. Pts with metastatic CRPC with progressive disease during or within 6 months of receiving docetaxel were eligible. Patupilone was initially given 10mg/m 2 IV every 3 weeks. PSA response rate (≥50% decline) was the primary endpoint (H0 = 15%, H1 = 25%, α = 0.1, β = 0.2). Secondary endpoints were measurable disease response, serial pain and analgesics scores, progression free survival (PFS) and overall survival (OS). Results: 83 pts were enrolled from March 2007-June 2008. 401 cycles administered (median 5, range 1–15). Baseline characteristics (range): median age 67 (47–85), PSA 212 (2.6–11520), hemoglobin 118 (89–160), median time to progression after docetaxel 1.0 months (0.0–6.0), number of prior chemotherapy regimens 1:2:3+ in 45:28:10 pts, ECOG PS 0–1:2 in 73:10 pts, disease in bone/lymph nodes/viscera in 76/47/14 pts respectively. In the first 6 pts, gastrointestinal serious adverse events (AE) occurred in 4 pts (diarrhea and vomiting) which lead to a dose reduction of patupilone to 8 mg/m 2 for subsequent patients. Grade 3/4 related adverse events at this dose included fatigue (16%), diarrhea (13%) and anorexia (5%). There were no grade 3/4 hematologic AEs. In 78 pts evaluable for PSA response, PSA declines of ≥30% and ≥50% have occurred in 44/78 (56%) and 35/78 (45%) with a confirmed PSA response in 25 pts (32%). Partial response occurred in 5% and stable disease in 64% of 44 evaluable pts. Pain response (2 point decline on 6 point scale) occurred in 36 (51%) of 71 pts eligible for analysis. Median PFS for PSA and non-PSA outcomes (measurable disease/symptomatic progression or death) was 7.6 months (3.7–11.5) and 5.6 months (3.9–7.3) respectively. Follow up for OS is continuing. Conclusions: Patupilone 8 mg/m 2 every 3 weeks was well tolerated and associated with encouraging PFS, PSA and pain responses in pts with docetaxel resistant/refractory disease. Further investigation of patupilone in this population is warranted. [Table: see text]
A Green Tea Component, Catechin, Induces Apoptosis of Human Myeloma Cells and Markedly Enhances Arsenic Trioxide-Induced Cytotoxicity Via Production of Reactive Oxygen Species (ROS).
Authors: Tomonori Nakazato, Keisuke Ito, Yoshitaka Miyakawa, Yasuo Ikeda, Masahiro Kizaki
Journal: Blood (2004)
구연 : 클라벨홀 ; 만성 간염 환장에서 혈청 표지자를 이용한 간경변증 예측모델 개발
Authors: 정재연, 조성원, 신승수, 박래웅, 김영배, 김동준, 황성규, 이연재, 조몽, 양진모, 바영년
Journal: Clinical and Molecular Hepatology (2008)
Combination Treatment with Imatinib and Mitoxantrone/Etoposide Is a Suitable Preparative Regimen before Allogeneic Transplantation in Patients with Myeloid Blast Crisis of Chronic Myeloid Leukemia.
Authors: Stefan Fruehauf, Julian Topaly, Eike C. Buss, Tanja Lahaye, Oliver G. Ottmann, Thomas Fischer, Bertold Emmerich, Ulrike Haus, Rudiger Hehlmann, Anthony D. Ho, Andreas Hochhaus
Journal: Blood (2005)
Immunology of Spontaneous Mammary Carcinomas in Mice
Authors: David H. Lavrin, Phyllis B. Blair, David W. Weiss
Journal: Cancer Research (1966)

A study was undertaken to determine whether the preneoplastic hyperplastic alveolar nodules of the mammary glands of C3H/Crgl and C3Hf/Crgl mice possess unique antigenic characteristics and whether a previous experience with the nodular tissues can bestow on isogenic animals a degree of heightened reactivity to later challenge with implants of mammary carcinomas arising spontaneously from the nodule outgrowths.

It was found that the C3Hf animals, which were free of biologically active mammary tumor virus, accepted grafts of a C3Hf nodular outgrowth with no evidence of rejection but reacted strongly against implants of either of 2 nodular outgrowths recently derived from the MTV[3-containing][1], isogenic C3H donors. The reaction against the C3H nodular tissue was much more pronounced in adult than in young C3Hf hosts.

A large proportion of C3Hf females immunized with C3H nodular tissue in adulthood proved to be resistant to subsequent challenge with implants of a mammary tumor that had developed from that outgrowth. In contrast, C3Hf females immunized with a C3Hf nodular outgrowth did not acquire heightened resistance against challenge with 2 mammary tumors originating in the C3Hf outgrowth.

It does not appear possible to explain these findings on the basis of a residual heterozygosis of isoantigenic characteristics between the C3H and C3Hf sublines. The results suggest that immunogenicity of spontaneous mammary carcinomas of mice, and of the preneoplastic nodular tissue, may reside at least partly in antigens possessed by, or induced by, the mammary tumor virus.

 [1]: #fn-3
Incidence of Blood Stream Infection Influenced by Dressing and Clinical Skin Care in a Patient with Neutropenia
Authors: Takamichi Shintani, Osamu Imataki, Hiroaki Ohnishi, Kaori Kondo, Yukiko Ohue, Fusako Waki, Akira Kitanaka, Yoshitsugu Kubota, Toshihiko Ishida, Terukazu Tanaka
Journal: Blood (2008)
如果不改变吸烟习惯，1／3的中国男性最终将死于烟草
Authors: 齐文安
Journal: BMJ (2009)

最近一项研究（CVD Prevention and Control 2009年1月20日，doi：10．1016／j．cvdpc．2008．12．001）指出，如果坐视如今的吸烟形势发展下去，在21世纪前50年，将有1亿中国人最终被烟草杀死。
Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial
Authors: Toru Kiguchi, Shinya Sato, Kensuke Usuki, Ken Ishiyama, Yoshikazu Ito, Takahiro Suzuki, Jun Taguchi, Shigeru Chiba, Nobuaki Dobashi, Akihiro Tomita, Hironori Harada, Hiroshi Handa, Shigeo Horiike, Tomoya Maeda, Mitsuhiro Matsuda, Motoshi Ichikawa, Tomoko Hata, Sumihisa Honda, Satoshi Iyama, Hitoshi Suzushima, Yukiyoshi Moriuchi, Toshiro Kurokawa, Takahiro Yamauchi, Hitoshi Kiyoi, Tomoki Naoe, Yasushi Miyazaki
Journal: Blood (2019)
Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy—Reply
Authors: Ralf E. Harskamp, John H. Alexander, Renato D. Lopes
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Sixty seconds on . . . mobile phone injuries
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Not quite. Researchers are more concerned with what injuries you might pick up from using your phone. A team from Rutgers New Jersey Medical School in the US studied mobile phone related injuries over 20 years (1998-2017) and found that the number had increased from a rate of around two to 27 per one million person years. Injuries included fractures, dislocations, …
Hasta güvenliği I. Kısım. Hasta güvenliği ve dermatolog
Authors: Dirk M. Elston, James S. Taylor, Brett Coldiron, cAntoinette F. Hood, Sandra I. Read, Jack S. Resneck, Robert S. Kirsner, John C. Maize, Sabra Sullivan, John Laskas, veC. William Hanke
Journal: Journal of the American Academy of Dermatology (2009)
The 11th International Workshop on Campylobacter, Helicobacter and related Organisms (CHRO), 2001
Authors: J Takkinen, A Ammon
Journal: Eurosurveillance (2003)

Over 700 participants from 54 countries attended the eleventh Campylobacter, Helicobacter and Related Organisms (CHRO) meeting in September 2001. This meeting was an opportunity to update and better understand the microbiological and epidemiological complexities of Campylobacter. The mechanism of pathogenesis of this bacteria is not yet fully understood and important progress was made in the microbiological characterisation. The availibility of over 100 different strain characteristics from various locations all over Europe, brought together by Campynet, is an invaluable tool for achieving this aim. There is increasing evidence to suggest that different risk factors exist for different species of Campylobacter. The link between antibiotic use in farm animals and increased resistance to some antimicrobials for humans still needs to be proved and some contradictory results reported on this issue.
Severity of Sickle Cell Disease: Modeling Interrelationships among Hemolysis, Pulmonary Hypertension and Risk of Death.
Authors: Paola Sebastiani, Vikki G. Nolan, Clinton T. Baldwin, Maria M. Abad-Grau, Ling Wang, Adeboye H. Adewoye, Lillian C. McMahon, Lindsay A. Farrer, James G. Taylor, Gregory J. Kato, Mark T. Gladwin, Martin H. Steinberg
Journal: Blood (2006)
Rhythmic Fluctuations in Levels of Liver Enzymes During Menstrual Cycles of Healthy Women and Effects of Body Weight
Authors: Chunwei Walter Lai, Sneha Jadhav, Basile Njei, Aijun Ye, Jean Wactawski-Wende, Sunni L. Mumford, Enrique F. Schisterman, Yaron Rotman
Journal: Clinical Gastroenterology and Hepatology (2019)
Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect
Authors: Jeroen A.C.M. Goos, Andrew Cho, Lukas M. Carter, Thomas R. Dilling, Maria Davydova, Komal Mandleywala, Simon Puttick, Abhishek Gupta, William S. Price, John F. Quinn, Michael R. Whittaker, Jason S. Lewis, Thomas P. Davis
Journal: Theranostics (2019)

Expression levels of biomarkers are generally unknown at initial diagnosis.The development of theranostic probes that do not rely on biomarker availability would expand therapy options for cancer patients, improve patient selection for nanomedicine and facilitate treatment of inoperable patients or patients with acquired therapy resistance.Herein, we report the development of star polymers, also known as nanostars, that allow for molecular imaging and/or endoradiotherapy based on passive targeting via the enhanced permeability and retention (EPR) effect.Methods: We synthesised a star copolymer, consisting of 7-8 centre-cross-linked arms that were modified with Gd 3+ for magnetic resonance imaging (MRI), and functionalised either with 89 Zr for in vivo quantification and positron emission tomography (PET) imaging, or with 177 Lu for endoradiotherapy. 1 H longitudinal relaxivities were determined over a continuum of magnetic field strengths ranging from 0.24 mT -0.94 T at 37 °C (nuclear magnetic relaxation dispersion (NMRD) profile) and T 1 -weighted MRI contrast enhancement was visualized at 3 T and 7 T. PET imaging and ex vivo biodistribution studies were performed in mice bearing tumours with high EPR (CT26) or low EPR (BxPC3) characteristics.Therapy studies were performed in mice with high EPR tumours and mean absorbed organ doses were estimated for a standard human model. Results:The star copolymer with Gd 3+ displayed a significantly superior contrast enhancement ability (T 1 = 0.60 s) compared to the standard clinical contrast agent Gadovist (T 1 = 1.0 s).Quantification of tumour accumulation using the radiolabelled nanostars in tumour-bearing mice demonstrated an exceptionally high uptake in tumours with high EPR characteristics (14.8 -21.7 %ID/g).Uptake of the star polymers in tumours with low EPR characteristics was significantly lower (P<0.001),suggesting passive tumour accumulation of the nanostars via the EPR effect.Survival of mice treated with high dose 177 Lu-labelled star polymers was significantly higher than survival of mice Ivyspring International
An epidemiology report for primary central nervous system tumors in adolescents and young adults: a nationwide population-based study in France, 2008–2013
Authors: Sam Ng, Sonia Zouaoui, Faiza Bessaoud, Valérie Rigau, Alexandre Roux, Amélie Darlix, Fabienne Bauchet, Hélène Mathieu-Daudé, Brigitte Trétarre, Dominique Figarella-Branger, Johan Pallud, Didier Frappaz, Thomas Roujeau, Luc Bauchet
Journal: Neuro-Oncology (2019)

Abstract Background Primary central nervous system tumors (PCNST) among adolescents and young adults (AYA, 15–39 y) have rarely been reported. We present a nationwide report of PCNST histologically confirmed in the French AYA population between 2008 and 2013. Methods Patients were identified through the French Brain Tumor Database (FBTDB), a national dataset that includes prospectively all histologically confirmed cases of PCNST in France. Patients aged 15 to 39 years with histologically confirmed PCNST diagnosed between 2008 and 2013 were included. For each of the 143 histological subtypes of PCNST, crude rates, sex, surgery, and age distribution were provided. To enable international comparisons, age-standardized incidence rates were adjusted to the world-standard, European, and USA populations. Results For 6 years, 9661 PCNST (males/females: 4701/4960) were histologically confirmed in the French AYA population. The overall crude rate was 8.15 per 100 000 person-years. Overall, age-standardized incidence rates were (per 100 000 person-years, population of reference: world/Europe/USA): 7.64/8.07/8.21, respectively. Among patients aged 15–24 years, the crude rate was 5.13 per 100 000. Among patients aged 25–39 years, the crude rate was 10.10 per 100 000. Age-standardized incidence rates were reported for each of the 143 histological subtypes. Moreover, for each histological subtype, data were detailed by sex, age, type of surgery (surgical resection or biopsy), and cryopreserved samples. Conclusion These data represent an exhaustive report of all histologically confirmed cases of PCNST with their frequency and distribution in the French AYA population in 2008–2013. For the first time in this age group, complete histological subtypes and rare tumor identification are detailed.
Cytogenetic Studies at Diagnosis in Polycythemia Vera: Clinical and JAK2V617F Allele Burden Correlates.
Authors: Naseema Gangat, Jacob J. Strand, Terra L. Lasho, Christy M. Finke, Ryan A. Knudson, Animesh Pardanani, Chin-Yang Li, Rhett P. Ketterling, Ayalew Tefferi
Journal: Blood (2007)
An imported case of e-cigarette or vaping associated lung injury in Barcelona
Authors: Gherzon Simón Casanova, Rosanel Amaro, Néstor Soler, Marcelo Sánchez, Joan Ramón Badía, Joan Albert Barberà, Alvar Agustí
Journal: European Respiratory Journal (2019)

Very recently, Layden et al. [1] published the first series of 53 patients with acute lung injury associated with the use of e-cigarettes (also known as vaping) in Wisconsin and Illinois, USA. To our knowledge, only a few cases of e-cigarette, or vaping, associated lung injury (EVALI) have been reported outside the USA (in Canada and Japan) and, so far, none in Europe [2]. Here we present the case of a 31-year-old woman who lived in Chicago (Illinois, USA) and arrived in Barcelona (Spain) on vacation on September 17, 2019 and, as detailed below, suffered EVALI. Vaping-induced lung injury diagnosed outside the USA <http://bit.ly/2L7WlyG>
Characterization and Optimization of Synthetic, VLDL Receptor Targeting, Antiangiogenic Peptides with TFPIc23-Like Activity.
Authors: Todd Hembrough, Kevin Yin, Art Hanson, Elizabeth Hahn-Dantona, Dudley Strickland, Stacy Plum, Genet Zemede, Greg Agoston, Christopher Holmes
Journal: Blood (2005)